S AIMS: The weight of response to neo-adjuvant therapies, to select candidates with hepatocellular carcinoma (HCC) for liver transplantation (LT) at acceptable risk of recurrence, remains partially unsolved for most of post-LT prediction models. Aim of this study was to embed radiological response in the Metroticket 2.0 model for post-LT prediction of "HCC-related death" to provide more usefulness in the modern clinical scenario.
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant / Cucchetti, Alessandro; Serenari, Matteo; Sposito, Carlo; Di Sandro, Stefano; Mosconi, Cristina; Vicentin, Ilaria; Garanzini, Enrico; Mazzaferro, Vincenzo; De Carlis, Luciano; Golfieri, Rita; Spreafico, Carlo; Vanzulli, Angelo; Buscemi, Vincenzo; Ravaioli, Matteo; Ercolani, Giorgio; Pinna, Antonio Daniele; Cescon, Matteo. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 73:2(2020), pp. 342-348. [10.1016/j.jhep.2020.03.018]
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant
Di Sandro, Stefano;Pinna, Antonio Daniele;
2020
Abstract
S AIMS: The weight of response to neo-adjuvant therapies, to select candidates with hepatocellular carcinoma (HCC) for liver transplantation (LT) at acceptable risk of recurrence, remains partially unsolved for most of post-LT prediction models. Aim of this study was to embed radiological response in the Metroticket 2.0 model for post-LT prediction of "HCC-related death" to provide more usefulness in the modern clinical scenario.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
